Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2006Expert Opinion on Investigational Drugs

Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases

View Full Paper
Ask AI
Bookmark
Share

Population

Patients requiring prevention or treatment of thromboembolic diseases

Design

Review

Authors

DKDagmar KubitzaBayer (United States)SHSylvia HaasVascular Medicine

Discussion

Loading...

Member takes

Implication

Novel factor Xa inhibitors remain investigational; leaves open their role versus established anticoagulants in thromboembolic disease.

Key Points

  • To review the pharmacological mechanisms and clinical development pipeline of direct and indirect factor Xa inhibitors as replacements for traditional anticoagulants.
  • Reviewed pharmacological profiles and clinical trial progress of emerging factor Xa targeting anticoagulants.
  • Evaluated antithrombin-dependent indirect inhibitors (fondaparinux and idraparinux) and direct inhibitors (rivaroxaban, DX-9065a, otamixaban, LY517717, and YM150).
  • Fondaparinux gained approval for prevention and treatment of venous thromboembolism, and idraparinux advanced to Phase III trials for venous thromboembolism and stroke prevention in atrial fibrillation.
  • Direct factor Xa inhibitor rivaroxaban completed Phase II investigations for venous thromboembolism prophylaxis in orthopedic surgery and initiated Phase III clinical trials alongside other direct agents.

Structured PICO

P
Population
Patients requiring prevention or treatment of thromboembolic diseases (e.g., venous thromboembolism, atrial fibrillation)
I
Intervention
Factor Xa inhibitors (indirect: fondaparinux, idraparinux; direct: rivaroxaban, DX-9065a, otamixaban, LY517717, YM150)

This review highlights the clinical development of novel factor Xa inhibitors as potential replacements for traditional anticoagulants in managing thromboembolic diseases.

Cite This Study

Kubitza et al. (2006) studied this question.

synapsesocial.com/papers/6a70eef353da1ffdb507b07fhttps://doi.org/10.1517/13543784.15.8.843

Topics

Anticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Importance of factor Xa in determining the procoagulant activity of whole-blood clots.1993 · 153 citations
  2. 2A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR.2005 · 27 citations
  3. 3Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism2003 · 890 citations
  4. 4The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor Xa1995 · 73 citations
  5. 5Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes2006 · 1,241 citations